Calendario›RANI›RT-114 is the RaniPill capsule…
RT-114 is the RaniPill capsule…
An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.
Ensayo de Rani Therapeutics Holdings, Inc. en Obesidad.
Más ensayos de: Obesidad.
- Fase
- Fase 1
- Estado
- Reclutando pacientes
- Participantes
- 60
- Centros
- 1
- Fin del objetivo primario
- dic 2026
previstos
estimado por el promotor
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en dic 2025.
Qué mide
To evaluate safety and tolerability of RT-114 by assessing treatment emergent adverse events (TEAEs) (Single dose and 8 weeks of repeat dosing) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe goal of this Phase 1 study is to evaluate the safety and tolerability of RT-114 in healthy volunteers. The main objectives are: Primary: To evaluate safety and tolerability of RT-114 when administered as single and multiple doses by assessing treatment emergent adverse events (TEAEs) in healthy volunteers Secondary: * To determine the pharmacokinetics of RT-114 administered as single and multiple doses * To determine the pharmacodynamic effects of RT-114 administered as multiple doses In the single dose portion of the study participants will either receive the drug via a subcutaneous injection or an oral pill (RT-114). In the repeat dose portion of the study participants will randomized to either RT-114 or a placebo.
Más ensayos de RANI
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Stelara | Fase 1 | Completado | nov 2023 (real) |
| RT-102 | Fase 1 | Completado | oct 2022 (real) |
| Pill Swallow Study | Sin fase asignada | Completado | ago 2021 (real) |
| RaniPill | Fase 1 | Completado | feb 2020 (real) |
Todos los de RANI, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06891287), actualizada en abr 2026.